1. Home
  2. TS vs UTHR Comparison

TS vs UTHR Comparison

Compare TS & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tenaris S.A.

TS

Tenaris S.A.

HOLD

Current Price

$56.12

Market Cap

27.3B

Sector

Industrials

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$485.54

Market Cap

23.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TS
UTHR
Founded
2001
1996
Country
Luxembourg
United States
Employees
N/A
N/A
Industry
Steel/Iron Ore
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.3B
23.1B
IPO Year
2002
1999

Fundamental Metrics

Financial Performance
Metric
TS
UTHR
Price
$56.12
$485.54
Analyst Decision
Buy
Buy
Analyst Count
5
14
Target Price
$58.80
★ $567.57
AVG Volume (30 Days)
★ 1.0M
491.0K
Earning Date
05-06-2026
05-06-2026
Dividend Yield
★ 2.80%
N/A
EPS Growth
N/A
★ 13.07
EPS
N/A
★ 13.07
Revenue
N/A
★ $1,483,300,000.00
Revenue This Year
$1.53
$6.39
Revenue Next Year
$3.59
$14.18
P/E Ratio
★ $12.59
$36.40
Revenue Growth
N/A
★ 2.38
52 Week Low
$33.71
$409.15
52 Week High
$64.60
$609.35

Technical Indicators

Market Signals
Indicator
TS
UTHR
Relative Strength Index (RSI) 53.63 40.53
Support Level $54.39 $463.88
Resistance Level $58.72 $487.91
Average True Range (ATR) 1.10 10.69
MACD -0.07 -1.30
Stochastic Oscillator 50.65 36.23

Price Performance

Historical Comparison
TS
UTHR

About TS Tenaris S.A.

Tenaris SA is engaged in the manufacture and supply of steel pipe products and related services for the energy industry and other industrial applications. The company has one reportable segment, Tubes, which includes the production and sale of steel tubular products such as OCTG, line pipe, and mechanical and structural tubes, mainly for the oil and gas industry. It operates an integrated network of manufacturing, research, and service facilities across the Americas, Europe, the Middle East, Asia, and Africa.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

Share on Social Networks: